In this Oct. 2009video on YouTube, Dr. Therese Bevers talks about new screening guidelines for cervical cancer. Women at increased risk have a higher chance of getting cervical cancer than women at average risk.
Women at increased risk include those who have:
History of cervical cancer or severe cervical dysplasia (pre-cancer)
Persistent Human Papilloma Virus (HPV) infection after age 30 (HPV testing not recommended in women younger than age 30)
An immune system that does not function properly
Been infected with Human Immunodeficiency Virus (HIV)
Guidelines from the American Cancer Society are that women 70 and older who have had three consecutive normal Pap smears and no abnormal results in the past 10 years may choose to stop Pap smears. Some women need to continue having Pap smears though … This includes women who received DES (diethylstilbestrol) during pregnancy … via FloridaToday
Thalidomide effects are visible at birth but DES acts like a time-bomb over 3 generations
Why do so few people know about DES and the damage its caused? DES seems to be in the shadows of thalidomide—so much so that it’s been referred to as the ‘silent thalidomide‘ in the press. The obvious difference between DES and thalidomide is that the effects of thalidomide are clearly visible at birth. DES acts more like a time-bomb … over three generations … yet few people know about DES … out of sight out of mind!
Age at natural Menopause in Women exposed to DiEthylStilbestrol in Utero
Women whose mothers took a common pregnancy drug are at risk of early menopause, research shows. A study of thousands of women revealed that those who were exposed to the ‘wonder drug’ DES in the womb were 50 per cent more likely to start the menopause early.
“Take a new estrogen promoted by the pharmaceutical companies. Add doctors ready to believe in another miracle drug. Take post-World War II women desperate to have a baby after miscarrying. Continue prescription for years. The result is the tragedy experienced by million of DES-exposed mothers, daughters, and son – and perhaps grandchildren. This is the story of what they did about the drug disaster that changed their lives.”
Retour à l’actualité du Distilbène, à l’occasion d’un congrès de gynécologie qui se tient à Paris. Ce médicament, indiqué dans les cas de grossesse difficile, provoque des malformations génitales chez les enfants des mères traitées.
Photo de comprimés de Distilbène.
Mère poussant landau dans jardin public.
Interview Mme Lascar, son bébé dans les bras, au sujet de sa grossesse difficile.
Reportage dans une famille dont les 4 enfants souffrent de malformations dues au Distilbène ; scène de famille ; interview de l’une des filles au sujet de ses craintes pour faire un enfant.
Entretien entre une gynéco et une patiente ; interview gynéco, Anne CABAU, au sujet des risques de malformations dus au Distilbène et de l’importance du dialogue mère-fille.
Brochure médicale éditée par le ministère au sujet de ce médicament.
The support group Réseau DES France was established in 1994. Their first DES public education campaign was launched in 1997 with the brochure “DES Distilbène® Exposure, the questions you ask yourself” aimed at raising DES awareness amongst the general public. Since 1994 Réseau DES France has engaged in many areas (information, cooperation, advocacy and lobbying, and DES lawsuits to name just a few). They’ve achieved many results and successes such a the right to longer maternity leave for DES pregnancies.